Anderson Chun On Tsang

Anderson Chun On Tsang

Auto-generated profile, based on publicly available information

Anderson Chun On Tsang

Division of Neurosurgery, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYilong Liu
Yilong Liu
ALAlex T. L. Leong
Alex T. L. Leong
YZYujiao Zhao
Yujiao Zhao
LXLinfang Xiao
Linfang Xiao
Henry Ka-Fung MakHenry Ka-Fung Mak
Henry Ka-Fung Mak
EWEd X. Wu
Ed X. Wu
Magnetic resonance imaging is a key diagnostic tool in modern healthcare, yet it can be cost-prohibitive given the high installation, maintenance and operation costs of the machinery. There are approximately seven scanners per million inhabitants and over 90% are concentrated in high-income countries. We describe an ultra-low-field brain MRI scanner that operates using a standard AC power outlet and is low cost to build. Using a permanent 0.055 Tesla Samarium-cobalt magnet and deep learning for cancellation of electromagnetic interference, it requires neither magnetic nor radiofrequency shielding cages. The scanner is compact, mobile, and acoustically quiet during scanning. We implement four standard clinical neuroimaging protocols (T1- and T2-weighted, fluid-attenuated inversion recovery like, and diffusion-weighted imaging) on this system, and demonstrate preliminary feasibility in diagnosing brain tumor and stroke. Such technology has the potential to meet clinical needs at point of care or in low and middle income countries.

30 August 2018 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
PNPatrick Nicholson
Patrick Nicholson
WBWaleed Brinjikji
Waleed Brinjikji
IRIvan Radovanovic
Ivan Radovanovic
CHChristopher Alan Hilditch
Christopher Alan Hilditch
ATAnderson Chun On Tsang
Anderson Chun On Tsang
SLStéphanie Lenck
Stéphanie Lenck
Background: Stenting of the intracranial venous sinuses is used as a treatment in certain cases of idiopathic intracranial hypertension (IIH). Interest in, and experience of, this technique is growing, particularly in recent years. We sought to provide an updated systematic review and meta-analysis of the use of venous stenting in these patients, examining clinical outcomes.Methods: A literature search of venous stenting in IIH patients was performed. Using random-effects meta-analysis, we evaluated the following outcomes: clinical resolution of papilledema; headaches and pulsatile tinnitus; recurrence of symptoms after stenting; and complications.Results: Twenty articles from 18 different centers were included. In a total of 474 patients. 418 were female (88%). The mean age of the patients was 35, while the mean body mass index (BMI) was 35 kg/m2. Median follow-up was 18 months. The overall rate of improvement in papilloedema was 93.7% (95% CI 90.5% to 96.9%), while the overall rate of improvement or resolution of headache was 79.6% (95% CI 73.3% to 85.9%). Pulsatile tinnitus resolved in 90.3% (95% CI 83.8% to 96.70%), while the overall rate of recurrence of IIH symptoms after stenting was 9.8% (95% CI 6.7% to 13%). The rate of major complications was 1.9% (95% CI 0.07% to 3.1%).Conclusions: Venous sinus stenting in patients with IIH who are refractory to medical therapy appears to have an excellent safety profile and is associated with significant improvements in headaches, pulsatile tinnitus, and papilledema.

1 July 2020 in Stroke
Verified
Journal Article
Closed access
PDF file
KTKay-Cheong Teo
Kay-Cheong Teo
William C.Y. LeungWilliam C.Y. Leung
William C.Y. Leung
YWYuen-Kwun Wong
Yuen-Kwun Wong
RLRoxanna K.C. Liu
Roxanna K.C. Liu
ACAnna H.Y. Chan
Anna H.Y. Chan
KLKui Kai Lau
Kui Kai Lau
Background and Purpose: The current coronavirus disease 2019 (COVID-19) pandemic represents a global public health crisis, disrupting emergency healthcare services. We determined whether COVID-19 has resulted in delays in stroke presentation and affected the delivery of acute stroke services in a comprehensive stroke center in Hong Kong. Methods: We retrospectively reviewed all patients with transient ischemic attack and stroke admitted via the acute stroke pathway of Queen Mary Hospital, Hong Kong, during the first 60 days since the first diagnosed COVID-19 case in Hong Kong (COVID-19: January 23, 2020–March 24, 2020). We compared the stroke onset to hospital arrival (onset-to-door) time and timings of inpatient stroke pathways with patients admitted during the same period in 2019 (pre–COVID-19: January 23, 2019–March 24, 2019). Results: Seventy-three patients in COVID-19 were compared with 89 patients in pre–COVID-19. There were no significant differences in age, sex, vascular risk factors, nor stroke severity between the 2 groups ( P >0.05). The median stroke onset-to-door time was ≈1-hour longer in COVID-19 compared with pre–COVID-19 (154 versus 95 minutes, P =0.12), and the proportion of individuals with onset-to-door time within 4.5 hours was significantly lower (55% versus 72%, P =0.024). Significantly fewer cases of transient ischemic attack presented to the hospital during COVID-19 (4% versus 16%, P =0.016), despite no increase in referrals to the transient ischemic attack clinic. Inpatient stroke pathways and treatment time metrics nevertheless did not differ between the 2 groups ( P >0.05 for all comparisons). Conclusions: During the early containment phase of COVID-19, we noted a prolongation in stroke onset to hospital arrival time and a significant reduction in individuals arriving at the hospital within 4.5 hours and presenting with transient ischemic attack. Public education about stroke should continue to be reinforced during the COVID-19 pandemic.

1 June 2023 in Stroke
Verified
Journal Article
Open access
KTKay Cheong Teo
Kay Cheong Teo
SFSze-Man Fong
Sze-Man Fong
William C.Y. LeungWilliam C.Y. Leung
William C.Y. Leung
ILIan Y.H. Leung
Ian Y.H. Leung
YWYuen-Kwun Wong
Yuen-Kwun Wong
KLKui-Kai Lau
Kui-Kai Lau
Background: Major intracerebral hemorrhage (ICH) trials have largely been unable to demonstrate therapeutic benefit in improving functional outcomes. This may be partly due to the heterogeneity of ICH outcomes based on their location, where a small strategic ICH could be debilitating, thus confounding therapeutic effects. We aimed to determine the ideal hematoma volume cutoff for different ICH locations in predicting ICH outcomes. Methods: We retrospectively analyzed consecutive ICH patients enrolled in the University of Hong Kong prospective stroke registry from January 2011 to December 2018. Patients with premorbid modified Rankin Scale score >2 or who underwent neurosurgical intervention were excluded. ICH volume cutoff, sensitivity, and specificity in predicting respective 6-month neurological outcomes (good [modified Rankin Scale score 0–2], poor [modified Rankin Scale score 4–6], and mortality) for specific ICH locations were determined using receiver operating characteristic curves. Separate multivariate logistic regression models were also conducted for each location-specific volume cutoff to determine whether these cutoffs were independently associated with respective outcomes. Results: Among 533 ICHs, the volume cutoff for good outcome according to ICH location was 40.5 mL for lobar, 32.5 mL for putamen/external capsule, 5.5 mL for internal capsule/globus pallidus, 6.5 mL for thalamus, 17 mL for cerebellum, and 3 mL for brainstem. ICH smaller than the cutoff for all supratentorial sites had higher odds of good outcomes (all P <0.05). Volumes exceeding 48 mL for lobar, 41 mL for putamen/external capsule, 6 mL for internal capsule/globus pallidus, 9.5 mL for thalamus, 22 mL for cerebellum, and 7.5 mL for brainstem were at greater risk of poor outcomes (all P <0.05). Mortality risks were significantly higher for volumes that exceeded 89.5 mL for lobar, 42 mL for putamen/external capsule, and 21 mL for internal capsule/globus pallidus (all P 0.8), except in predicting good outcome for cerebellum. Conclusions: ICH outcomes differed with location-specific hematoma size. Location-specific volume cutoff should be considered in patient selection for ICH trials.

3 April 2023 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
VLVick Lau
Vick Lau
LXLinfang Xiao
Linfang Xiao
YZYujiao Zhao
Yujiao Zhao
SSShi Su
Shi Su
YDYe Ding
Ye Ding
EWEd X. Wu
Ed X. Wu
Purpose: Recent development of ultra‐low‐field (ULF) MRI presents opportunities for low‐power, shielding‐free, and portable clinical applications at a fraction of the cost. However, its performance remains limited by poor image quality. Here, a computational approach is formulated to advance ULF MR brain imaging through deep learning of large‐scale publicly available 3T brain data.Methods: A dual‐acquisition 3D superresolution model is developed for ULF brain MRI at 0.055 T. It consists of deep cross‐scale feature extraction, attentional fusion of two acquisitions, and reconstruction. Models for T1‐weighted and T2‐weighted imaging were trained with 3D ULF image data sets synthesized from the high‐resolution 3T brain data from the Human Connectome Project. They were applied to 0.055T brain MRI with two repetitions and isotropic 3‐mm acquisition resolution in healthy volunteers, young and old, as well as patients.Results: The proposed approach significantly enhanced image spatial resolution and suppressed noise/artifacts. It yielded high 3D image quality at 0.055 T for the two most common neuroimaging protocols with isotropic 1.5‐mm synthetic resolution and total scan time under 20 min. Fine anatomical details were restored with intrasubject reproducibility, intercontrast consistency, and confirmed by 3T MRI.Conclusion: The proposed dual‐acquisition 3D superresolution approach advances ULF MRI for quality brain imaging through deep learning of high‐field brain data. Such strategy can empower ULF MRI for low‐cost brain imaging, especially in point‐of‐care scenarios or/and in low‐income and mid‐income countries.

9 March 2019 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
MMMario Martínez-Galdámez
Mario Martínez-Galdámez
ABAlessandra Biondi
Alessandra Biondi
VKVladimir Kalousek
Vladimir Kalousek
VPVitor M Pereira
Vitor M Pereira
GIGiuseppe Ianucci
Giuseppe Ianucci
RCRené Chapot
René Chapot
Purpose The aim of our study was to assess the technical success and the safety of this new low-profile flow diverter Silk Vista Baby (SVB) by evaluating the intraprocedural and periprocedural complication rate. Material/methods Clinical, procedural, and angiographic data were analyzed. Results: 41 consecutive patients (28 women; age average 50.5 years) with 43 aneurysms were treated with SVB. Aneurysm sizes were classified by their maximum diameter, with an average size of 9.5 mm (range 2–30 mm). Thirty-four cases were unruptured. five aneurysms previously ruptured, had recurrence after the initial coiling. There were two ruptured cases. Aneurysms' locations were: M1 segment (five cases), M2 segment (three cases), M3 segment (one case), middle cerebral artery (MCA) bifurcation (six cases), carotid-T (two cases), anterior communicating artery/A1/A2 (11 cases), pericallosal artery (four cases), supraclinoid ICA (two cases), PCom (one case), V4 segment (three cases), PCA (three cases), SCA (one case), and PICA (one case). We had five intraprocedural complications which resolved without clinical consequences and three events postprocedural events. Initial occlusion rates were: eight aneurysms (18.6%) were completely occluded, five aneurysms (11.6%) showed near-complete occlusion, four cases (9.3%) showed incomplete filling, and 26 cases (60.4%) showed persisting filling. The mRS score at discharge from the hospital did not change from the admission mRS score. Conclusion Our study demonstrated that the use of the new low-profile flow diverter, SVB device, for the treatment of intracranial aneurysms is feasible and technically safe.